Explore 3 Stock Ideas & Industry Insights Download Free Report

SILEX Systems Ltd

Company price
2.97 AUD -0.23 ( 7.19%)
Last update at 2026-11-06T05:48:00Z
VOLUME
2221035
Market Cap
892.12M

Momentum Score

…

Silex Systems Limited, a technology commercialization company, engages in the research and development, commercialization, and license of SILEX laser enrichment technology in Australia, the United States, and the United Kingdom. It operates through three segments: Silex Systems, Translucent, and Silex USA. The company also sells its cREO technology. In addition, it develops its laser-based enrichment technology for use in various applications comprising uranium production and enrichment for nuclear power; silicon enrichment for silicon quantum computing; and medical isotope enrichment for new cancer therapies. Silex Systems Limited was incorporated in 1987 and is based in Lucas Heights, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.86
Low
3.03
High
52 Week Price Range
2.98
Low
10.09
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Silex Systems is an Australian company that develops and licenses laser-based isotope separation technology, mainly for uranium enrichment. Growth drivers include commercial adoption of the SILEX process, licensing revenue from partners, and sustained demand for low-carbon nuclear fuel, which may attract investors seeking exposure to specialized enabling technology.
Key risks are commercialization and execution uncertainty, regulatory and licensing hurdles in the nuclear supply chain, dependence on a small number of partners and capital-intensive project funding, and sensitivity to uranium prices and policy shifts.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.20
Dividend Yield
-
Revenue TTM
18.87M
Revenue Per Share
0.07
Gross Profit TTM
3.96M
Debt / Equity
0.00
ROE
-26.44%
Net Debt
-15.39M
ROCE
-2.23%
Diluted EPS TTM
-0.14

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -41.75M -42.56M -22.73M -17.36M -9.46M
Net income -38.62M -42.56M -22.73M -17.36M -9.46M
Selling general administrative - 10.79M 1.12M 7.69M 5.97M
Selling and marketing expenses - - 0.16M - -
Gross profit -0.50M 6.79M -5.09M -4.27M -2.86M
Reconciled depreciation - 0.50M 0.43M 0.38M 0.44M
Ebit -4.49M -42.47M -22.69M -17.28M -9.46M
Ebitda -3.99M -41.97M -22.27M -16.89M -9.02M
Depreciation and amortization 0.51M 0.50M 0.43M 0.38M 0.44M
Operating income -4.49M -12.84M -10.11M -3.08M -2.28M
Other operating expenses 18.20M 19.64M 16.22M 29.37M 16.06M
Interest expense 0.07M 0.09M 0.04M 0.05M 0.02M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 4.94M 6.04M 16.65M 0.18M
Net interest income - 4.85M 6.00M 2.35M 0.16M
Income tax expense -3.13M - -23.22M -13.00M -5.11M
Total revenue 13.71M 6.79M 6.11M 6.12M 4.22M
Total operating expenses 3.99M 19.64M 5.02M 12.75M 8.72M
Cost of revenue 14.21M 12.47M 11.20M 10.40M 7.08M
Total other income expense net -37.26M -29.71M -12.62M -13.08M -5.12M
Net income from continuing ops - -42.56M -22.73M -17.36M -9.46M
Net income applicable to common shares - -42.56M -22.73M -17.36M -9.46M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 208.07M 98.96M 141.56M 152.20M 54.12M
Other current assets 0.87M 1.07M 1.13M 0.83M 0.33M
Total liab 6.88M 8.01M 9.62M 3.51M 3.57M
Total stockholder equity 201.20M 90.95M 131.94M 148.69M 50.55M
Other current liab 1.43M 5.62M 1.56M 2.38M 1.12M
Common stock 539.79M 392.70M 390.67M 386.75M 271.54M
Capital stock - 392.70M 390.67M 386.75M 271.54M
Retained earnings -355.60M -314.69M -272.14M -249.40M -232.04M
Other liab - - - 0.09M 0.07M
Cash 16.03M 19.75M 18.89M 2.86M 5.04M
Total current liabilities 6.46M 7.27M 8.62M 2.88M 2.72M
Current deferred revenue 3.49M - 4.45M -0.23M 0.92M
Net debt -15.39M -18.84M -17.71M -2.09M -4.05M
Short term debt 0.31M 0.56M 0.27M 0.23M 0.20M
Short long term debt total 0.64M 0.91M 1.18M 0.77M 0.98M
Other stockholder equity - - - -137.35M -39.50M
Property plant equipment - - - 1.04M 1.31M
Total current assets 190.20M 89.67M 126.73M 147.53M 49.68M
Long term investments - 8.05M 13.27M 3.63M 3.12M
Net tangible assets - - - 148.69M 50.55M
Short term investments 164.71M 62.21M 98.11M 137.88M 41.50M
Net receivables 8.59M 6.64M 8.61M 5.96M 2.82M
Accounts payable 1.22M 1.09M 2.35M 0.50M 0.48M
Accumulated other comprehensive income 17.00M 12.94M 13.41M 11.34M 11.04M
Non currrent assets other - - - -4.67M -4.43M
Non current assets total 17.87M 9.29M 14.83M 4.67M 4.43M
Capital lease obligations - 0.91M 1.18M 0.77M 0.98M
Long term debt total - - - 0.54M 0.78M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -2.61M 7.56M -114.40M -39.94M
Change to liabilities - - - 0.10M 0.59M
Total cashflows from investing activities -155.67M -2.61M 7.56M -114.40M -40.06M
Net borrowings - - - -0.23M -0.30M
Total cash from financing activities 143.93M 0.40M 2.34M 114.55M 38.20M
Change to operating activities - - - -3.17M -0.14M
Net income -38.62M -42.56M -22.73M -17.36M -9.46M
Change in cash -27.42M 0.86M 16.03M -2.18M -1.37M
Begin period cash flow 43.46M 18.89M 2.86M 5.04M 6.40M
End period cash flow 16.03M 19.75M 18.89M 2.86M 5.04M
Total cash from operating activities 8.18M 3.02M 6.14M -2.34M 0.41M
Issuance of capital stock - 0.70M 2.59M 114.78M 38.50M
Depreciation 0.51M - 0.43M 0.38M 0.44M
Other cashflows from investing activities 3.43M 0.00M 0.02M -114.30M -39.94M
Change to account receivables -1.95M 1.97M -2.64M -0.42M -0.11M
Sale purchase of stock - 0.70M 2.59M 114.78M 38.50M
Other cashflows from financing activities -0.30M -0.29M -0.25M -0.23M -0.30M
Change to netincome - - - 18.13M 9.08M
Capital expenditures 0.11M 0.16M 0.29M 0.09M 0.13M
Change in working capital -2.61M 0.69M 2.76M -0.42M -0.11M
Stock based compensation - - - 1.86M 1.08M
Other non cash items 48.91M 2.33M 28.87M 14.64M 9.44M
Free cash flow 8.08M 2.86M 5.85M -2.43M 0.29M

Peer Comparison*

Sector: Technology Industry: Semiconductors

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SLX
SILEX Systems Ltd
-0.23
7.19%
2.97 - 769.23 47.29 4.18 49.82 -62.48
WBT
Weebit Nano Ltd
-0.20
8.55%
2.14 - - 37.25 3.41 23.39 -28.24
BRN
Brainchip Holdings Ltd
-0.01
4.76%
0.10 - - 120.58 8.94 75.29 589.01
AXE
Archer Materials Ltd
0.03
15.62%
0.18 - 15.95 19.35 4.23 4502.73 -4.80
4DS
4DS Memory Ltd
-
-%
0.01 - - 34.19 2.39 1000000.00 -7.27

Profile*

SILEX Systems Ltd

Silex Systems Limited, a technology commercialization company, engages in the research and development, commercialization, and license of SILEX laser enrichment technology in Australia, the United States, and the United Kingdom. It operates through three segments: Silex Systems, Translucent, and Silex USA. The company also sells its cREO technology. In addition, it develops its laser-based enrichment technology for use in various applications comprising uranium production and enrichment for nuclear power; silicon enrichment for silicon quantum computing; and medical isotope enrichment for new cancer therapies. Silex Systems Limited was incorporated in 1987 and is based in Lucas Heights, Australia.

Building 64, Lucas Heights, NSW, Australia, 2234

61 2 9704 8888

Name Title Year Born
Dr. Michael P. Goldsworthy B.Sc., BSc (Hons), FAIP, GAICD, M.Sc., MSc, Ph.D. CEO, MD & Exec. Director 1958
Ms. Julie E. Ducie B.Bus., C.A., CA, GAICD, M.B.A. CFO & Company Sec. NA
Dr. Geordie Graetz Chief Commercial Officer NA
Dr. Michael P. Goldsworthy B.Sc., BSc (Hons), FAIP, GAICD, M.Sc., MSc, Ph.D. CEO, MD & Executive Director 1958
Ms. Julie E Russell B.Bus., C.A., CA, GAICD, M.B.A. CFO & Company Secretary NA
Dr. Geordie Graetz M.A., Ph.D. Chief Commercial Officer NA
Dr. Michael P. Goldsworthy B.Sc., BSc (Hons), FAIP, GAICD, M.Sc., MSc, Ph.D. CEO, MD & Executive Director 1958
Ms. Julie E Russell B.Bus., C.A., CA, GAICD, M.B.A. CFO & Company Secretary NA
Dr. Geordie Graetz M.A., Ph.D. Chief Commercial Officer NA
Dr. Michael P. Goldsworthy B.Sc., BSc (Hons), FAIP, GAICD, M.Sc., MSc, Ph.D. CEO, MD & Executive Director 1958

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…